NCT06344715 2024-04-03Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.SL VAXiGENPhase 1 Recruiting78 enrolled
NCT04054752 2023-11-02Vaccine Response With NT-I7National Institutes of Health Clinical Center (CC)Phase 1 Withdrawn